09:15

Registration

09:30

WELCOME

Inga Kadish (organizing comittee)

Heersink School of Medicine, Dept. Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, USA

09:35

Welcome addresses

NN (Heinrich Heine University Düsseldorf, Germany)

NN (Forschungszentrum Jülich GmbH, Germany)

Michael Lorrain, Chairman Alzheimer Forschung Initiative e.V., Düsseldorf, Germany

SESSION I: Anti-amyloid antibody trials, outcome, meaningfulness and treatment costs

09:45

Neurobiology of Alzheimer disease in people with Down syndrome

Elizabeth Head

Department of Pathology and Laboratory Medicine, University of California, Irvine,
CA, USA

10:35

Coffee break

11:00

Lutz Frölich and Lucretia Hausner

Department of Geriatric Psychiatry, Zentralinstitut für Seelische Gesundheit
Mannheim, University of Heidelberg, Mannheim, Germany.

11:50

Towards a future where Alzheimer’s disease is stopped before onset of dementia

Wiesje van der Flier

Alzheimer Centre, Department of Neurology, Amsterdam Neuroscience,
Vrije Universiteit Amsterdam, Netherlands

12:40

NN

Talk by early career scientist (selected from the poster abstracts submitted)

13:00

Lunch break

13:50

Key findings from two Phase III studies evaluating the efficacy and safety of subcutaneous gantenerumab in early Alzheimer’s disease (AD)

Frank Boess

F. Hoffmann-La Roche Ltd., Product Development Neuroscience, Basel, Switzerland

SESSION II: New concepts in therapy

14:40

NN

Talk by early career scientist (selected from the poster abstracts submitted)

15:00

Vaccination with modified fungal proteins mimicking conformational epitopes on alpha-synuclein fibrils prolongs survival in mouse models of Parkinson's disease

Erdem Tamgüney^a and Holger Wille^b

^aInstitut für Physikalische Biologie, Heinrich Heine University Düsseldorf and      Forschungszentrum Jülich, IBI-7: Structural Biochemistry, Jülich, Germany

^bCentre for Prions and Protein Folding Diseases & Department of Biochemistry,
University of Alberta, Edmonton, Canada

15:50

Antje Willuweit

Priavoid GmbH, Düsseldorf, Germany and Institute of Neuroscience and Medicine
(INM-4), Forschungszentrum Jülich, Jülich, Germany

16:40

NN

Talk by early career scientist (selected from the poster abstracts submitted)

17:00

Break

PUBLIC SCIENCE LECTURE
jointly organized with Alzheimer Forschung Initiative e.V. (AFI)

18:15

Gemeinsam gegen das Vergessen: Informationsabend zu neuen Alzheimer-Therapien

Frank Jessen

Department of Psychiatry, Medical Faculty University of Cologne and German Center
for Neurodegenerative Diseases (DZNE), Bonn, Germany

SESSION III: Biomarkers and amyloid clearance

09:30

How fluid biomarkers revolutionize the diagnosis of Alzheimer´s disease

Oliver Peters

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin and German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany

10:20

NN

Talk by early career scientist (selected from the poster abstracts submitted)

10:40

Coffee break

11:00

Stage 2 of AD as a target for DMT treatment

Frank Jessen

Department of Psychiatry, Medical Faculty University of Cologne and German Center
for Neurodegenerative Diseases (DZNE), Bonn, Germany

11:50

Oligomers count

Oliver Bannach

attyloid GmbH, Düsseldorf, Germany and Forschungszentrum Jülich, IBI-7: Structural Biochemistry, Jülich, Germany

12:40

Lunch break

SESSION IV: Basic science: amyloid structures and early aggregation steps incl. LLPS

13:30

Exploiting cross-amyloid interactions to design inhibitors of amyloid self-assembly

Aphrodite Kapurniotu

Division of Peptide Biochemistry, TUM School of Life Sciences, Technical University of Munich (TUM), Freising, Germany.

14:20

Flash Talks

15 poster presenters, 1 min time per talk.

14:40

Phase transitions of Tau: how liquid condensates catalyze pathological aggregation

Susanne Wegmann

German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany

15:30

Flash Talks,

15 poster presenters, 1 min time per talk.

15:50

Funding Opportunities: Alzheimer Forschung Initiative e.V. (AFI)

Jochen Walter

Klinik für Neurologie, Universitätsklinikum Bonn, Germany

POSTER SESSION

16:00

Poster session with guided poster tours and finger food buffet

SESSION IV: Basic science: amyloid structures and early aggregation steps incl. LLPS

09:30

Structure dynamics of human PLCγ2 in auto-inhibition

Julie Chen and John Wang

Eisai, Center for Genetics Guided Dementia Discovery, Cambridge, Massacusetts, USA

10:20

NN

Talk by early career scientist (selected from the poster abstracts submitted)

CV – BEHIND THE SCENES

10:40

CV – behind the scenes

Four presentations by invited speakers 15 min each.

The speakers report on their personal journey in academic or industrial research.

11:40

Lunch break

SESSION IV: Basic science: amyloid structures and early aggregation steps incl. LLPS

12:10

Sjors Scheres

MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, UK

13:00

Structures and mechanisms of formation of amyloid-beta assemblies

Robert Tycko

Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and
Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA

13:50

Sequence and structural features that control aggregation into amyloid

Sheena Radford

Astbury Centre for Structural Molecular Biology, University of Leeds, United Kingdom

POSTER PRIZE AWARD

14:40

Poster prizes

sponsored by Alzheimer Forschung Initiative e.V.

14:50

Closing remarks

Inga Kadish^a, Thomas van Groen^b and Dieter Willbold^c (organizing committee)

^aHeersink School of Medicine, Dept. Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, USA
^bDept. Pediatrics-Neonatology, University of Alabama at Birmingham, USA
^cHeinrich Heine University Düsseldorf, Institut für Physikalische Biologie and Forschungszentrum Jülich, IBI-7: Structural Biochemistry, Jülich, Germany